<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>88(10)</volume><submitter>Han K</submitter><pubmed_abstract>&lt;h4>Aim&lt;/h4>To characterize cabotegravir population pharmacokinetics using data from phase 1, 2 and 3 studies and evaluate the association of intrinsic and extrinsic factors with pharmacokinetic variability.&lt;h4>Methods&lt;/h4>Analyses were implemented in NONMEM and R. Concentrations below the quantitation limit were modelled with likelihood-based approaches. Covariate relationships were evaluated using forward addition (P &lt; .01) and backward elimination (P &lt; .001) approaches. The impact of each covariate on trough and peak concentrations was evaluated through simulations. External validation was performed using prediction-corrected visual predictive checks.&lt;h4>Results&lt;/h4>The model-building dataset included 23 926 plasma concentrations from 1647 adult HIV-1-infected (72%) and uninfected (28%)</pubmed_abstract><journal>British journal of clinical pharmacology</journal><pagination>4607-4622</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9543358</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.</pubmed_title><pmcid>PMC9543358</pmcid><pubmed_authors>Landovitz RJ</pubmed_authors><pubmed_authors>Han K</pubmed_authors><pubmed_authors>Benn PD</pubmed_authors><pubmed_authors>Marzinke MA</pubmed_authors><pubmed_authors>Paul P</pubmed_authors><pubmed_authors>Moore KP</pubmed_authors><pubmed_authors>Ford SL</pubmed_authors><pubmed_authors>Xiong Y</pubmed_authors><pubmed_authors>Patel P</pubmed_authors><pubmed_authors>Baker M</pubmed_authors><pubmed_authors>Seal CS</pubmed_authors><pubmed_authors>Lovern M</pubmed_authors><pubmed_authors>Spreen WR</pubmed_authors><pubmed_authors>D'Amico RD</pubmed_authors><pubmed_authors>Cutrell AG</pubmed_authors></additional><is_claimable>false</is_claimable><name>Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.</name><description>&lt;h4>Aim&lt;/h4>To characterize cabotegravir population pharmacokinetics using data from phase 1, 2 and 3 studies and evaluate the association of intrinsic and extrinsic factors with pharmacokinetic variability.&lt;h4>Methods&lt;/h4>Analyses were implemented in NONMEM and R. Concentrations below the quantitation limit were modelled with likelihood-based approaches. Covariate relationships were evaluated using forward addition (P &lt; .01) and backward elimination (P &lt; .001) approaches. The impact of each covariate on trough and peak concentrations was evaluated through simulations. External validation was performed using prediction-corrected visual predictive checks.&lt;h4>Results&lt;/h4>The model-building dataset included 23 926 plasma concentrations from 1647 adult HIV-1-infected (72%) and uninfected (28%)</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-04T20:03:48.534Z</modification><creation>2025-04-04T20:03:48.534Z</creation></dates><accession>S-EPMC9543358</accession><cross_references><pubmed>35695476</pubmed><doi>10.1111/bcp.15439</doi></cross_references></HashMap>